No products in the cart.
Pre-made Obiltoxaximab benchmark antibody ( Whole mAb, anti-Anthrax Protective Antigen therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-384
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Obiltoxaximab biosimilar, Whole Mab: Anti-Anthrax Protective Antigen therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Obiltoxaximab, sold under the brand name Anthim, is a monoclonal antibody medication designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).
| Products Name (INN Index) | Pre-Made Obiltoxaximab biosimilar, Whole Mab: Anti-Anthrax Protective Antigen therapeutic antibody |
|---|---|
| INN Name | Obiltoxaximab |
| Target | Anthrax Protective Antigen |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Elusys Therapeutics |
| Conditions Approved | Anthrax |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | Anthrax Protective Antigen |
| Package |
Previous slide
Next slide
